Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment - Part 2

Denis A. Evans, Francine Grodstein, David Loewenstein, Jeffrey Kaye, Sandra Weintraub

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Dementia of the Alzheimer's type (DAT) is a major public health threat in developed countries where longevity has been extended to the eighth decade of life. Estimates of prevalence and incidence of DAT vary with what is measured, be it change from a baseline cognitive state or a clinical diagnostic endpoint, such as Alzheimer's disease. Judgment of what is psychometrically "normal" at the age of 80 years implicitly condones a decline from what is normal at the age of 30. However, because cognitive aging is very heterogeneous, it is reasonable to ask "Is 'normal for age' good enough to screen for DAT or its earlier precursors of cognitive impairment?" Cost containment and accessibility of ascertainment methods are enhanced by well-validated and reliable methods such as screening for cognitive impairment by telephone interviews. However, focused assessment of episodic memory, the key symptom associated with DAT, might be more effective at distinguishing normal from abnormal cognitive aging trajectories. Alternatively, the futuristic "Smart Home," outfitted with unobtrusive sensors and data storage devices, permits the moment-to-moment recording of activities so that changes that constitute risk for DAT can be identified before the emergence of symptoms.

Original languageEnglish (US)
Pages (from-to)110-123
Number of pages14
JournalAlzheimer's and Dementia
Volume7
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Alzheimer Disease
Costs and Cost Analysis
Population
Episodic Memory
Cost Control
Information Storage and Retrieval
Developed Countries
Cognitive Dysfunction
Public Health
Interviews
Equipment and Supplies
Incidence
Cognitive Aging

Keywords

  • Alzheimer's disease
  • Cognitive assessment
  • Cognitive function
  • Cognitive impairment
  • Dementia
  • Monitoring system
  • Technology

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment - Part 2. / Evans, Denis A.; Grodstein, Francine; Loewenstein, David; Kaye, Jeffrey; Weintraub, Sandra.

In: Alzheimer's and Dementia, Vol. 7, No. 1, 01.2011, p. 110-123.

Research output: Contribution to journalArticle

Evans, Denis A. ; Grodstein, Francine ; Loewenstein, David ; Kaye, Jeffrey ; Weintraub, Sandra. / Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment - Part 2. In: Alzheimer's and Dementia. 2011 ; Vol. 7, No. 1. pp. 110-123.
@article{1a7dbde287ed4346ba1c3bc99f8831f0,
title = "Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment - Part 2",
abstract = "Dementia of the Alzheimer's type (DAT) is a major public health threat in developed countries where longevity has been extended to the eighth decade of life. Estimates of prevalence and incidence of DAT vary with what is measured, be it change from a baseline cognitive state or a clinical diagnostic endpoint, such as Alzheimer's disease. Judgment of what is psychometrically {"}normal{"} at the age of 80 years implicitly condones a decline from what is normal at the age of 30. However, because cognitive aging is very heterogeneous, it is reasonable to ask {"}Is 'normal for age' good enough to screen for DAT or its earlier precursors of cognitive impairment?{"} Cost containment and accessibility of ascertainment methods are enhanced by well-validated and reliable methods such as screening for cognitive impairment by telephone interviews. However, focused assessment of episodic memory, the key symptom associated with DAT, might be more effective at distinguishing normal from abnormal cognitive aging trajectories. Alternatively, the futuristic {"}Smart Home,{"} outfitted with unobtrusive sensors and data storage devices, permits the moment-to-moment recording of activities so that changes that constitute risk for DAT can be identified before the emergence of symptoms.",
keywords = "Alzheimer's disease, Cognitive assessment, Cognitive function, Cognitive impairment, Dementia, Monitoring system, Technology",
author = "Evans, {Denis A.} and Francine Grodstein and David Loewenstein and Jeffrey Kaye and Sandra Weintraub",
year = "2011",
month = "1",
doi = "10.1016/j.jalz.2010.11.008",
language = "English (US)",
volume = "7",
pages = "110--123",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Reducing case ascertainment costs in U.S. population studies of Alzheimer's disease, dementia, and cognitive impairment - Part 2

AU - Evans, Denis A.

AU - Grodstein, Francine

AU - Loewenstein, David

AU - Kaye, Jeffrey

AU - Weintraub, Sandra

PY - 2011/1

Y1 - 2011/1

N2 - Dementia of the Alzheimer's type (DAT) is a major public health threat in developed countries where longevity has been extended to the eighth decade of life. Estimates of prevalence and incidence of DAT vary with what is measured, be it change from a baseline cognitive state or a clinical diagnostic endpoint, such as Alzheimer's disease. Judgment of what is psychometrically "normal" at the age of 80 years implicitly condones a decline from what is normal at the age of 30. However, because cognitive aging is very heterogeneous, it is reasonable to ask "Is 'normal for age' good enough to screen for DAT or its earlier precursors of cognitive impairment?" Cost containment and accessibility of ascertainment methods are enhanced by well-validated and reliable methods such as screening for cognitive impairment by telephone interviews. However, focused assessment of episodic memory, the key symptom associated with DAT, might be more effective at distinguishing normal from abnormal cognitive aging trajectories. Alternatively, the futuristic "Smart Home," outfitted with unobtrusive sensors and data storage devices, permits the moment-to-moment recording of activities so that changes that constitute risk for DAT can be identified before the emergence of symptoms.

AB - Dementia of the Alzheimer's type (DAT) is a major public health threat in developed countries where longevity has been extended to the eighth decade of life. Estimates of prevalence and incidence of DAT vary with what is measured, be it change from a baseline cognitive state or a clinical diagnostic endpoint, such as Alzheimer's disease. Judgment of what is psychometrically "normal" at the age of 80 years implicitly condones a decline from what is normal at the age of 30. However, because cognitive aging is very heterogeneous, it is reasonable to ask "Is 'normal for age' good enough to screen for DAT or its earlier precursors of cognitive impairment?" Cost containment and accessibility of ascertainment methods are enhanced by well-validated and reliable methods such as screening for cognitive impairment by telephone interviews. However, focused assessment of episodic memory, the key symptom associated with DAT, might be more effective at distinguishing normal from abnormal cognitive aging trajectories. Alternatively, the futuristic "Smart Home," outfitted with unobtrusive sensors and data storage devices, permits the moment-to-moment recording of activities so that changes that constitute risk for DAT can be identified before the emergence of symptoms.

KW - Alzheimer's disease

KW - Cognitive assessment

KW - Cognitive function

KW - Cognitive impairment

KW - Dementia

KW - Monitoring system

KW - Technology

UR - http://www.scopus.com/inward/record.url?scp=78751670577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751670577&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2010.11.008

DO - 10.1016/j.jalz.2010.11.008

M3 - Article

C2 - 21255748

AN - SCOPUS:78751670577

VL - 7

SP - 110

EP - 123

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 1

ER -